ELOXX PHARMACEUTICALS INC (ELOX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Employees:
29
10210 CAMPUS POINT DRIVE,, SUITE 150, SAN DIEGO, CA 92121
(858) 909-0749

N/A

Data derived from most recent annual or quarterly report
Market Cap 20.614 Million Shares Outstanding86.252 Million Avg 30-day Volume 234.633 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.76
Price to Revenue0.0 Debt to Equity1.0371 EBITDA-68.209 Million
Price to Book Value4.1517 Operating Margin0.0 Enterprise Value20.572 Million
Current Ratio2.198 EPS Growth-0.178 Quick Ratio2.074
1 Yr BETA 0.7714 52-week High/Low 2.1 / 0.21 Profit Margin0.0
Operating Cash Flow Growth-53.8304 Altman Z-Score-11.7485 Free Cash Flow to Firm -36.807 Million
Earnings Report2022-08-15
View SEC Filings from ELOX instead.

View recent insider trading info

Funds Holding ELOX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ELOX BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-16:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-05:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2021-11-17:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-05:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
  • 8-K: filed on 2021-09-30:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-13:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2021-08-20:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    RUBIN STEVEN D

    • Director
    20,000 2022-06-15 1

    PAREKH RAJESH B

    • Director
    20,000 2022-06-15 1

    KARIV TOMER

    • Director
    20,000 2022-06-15 1

    NUSSBAUM RAN

    • Director
    20,000 2022-06-15 1

    VEINRIB GADI

    • Director
    20,000 2022-06-15 1

    AVNUR ZAFRIRA

    • Director
    20,000 2022-06-15 1

    SEEHRA JASBIR

    • Director
    20,000 2022-06-15 1

    WALTS ALAN EDMUND

    • Director
    20,000 2022-06-15 2

    MODUR VIJAY HEAD OF R&D

    154,953 2021-12-01 1

    AGGARWAL SUMIT PRESIDENT AND CEO

    197,225 2021-12-01 1

    GEFFKEN DANIEL E. INTERIM CFO

    50,000 2021-11-29 1

    BELLOFF NEIL S. COO, GENERAL COUNSEL &CORP SEC

    42,074 2021-07-30 1

    PONTIFAX MANAGEMENT 4 G.P. (2015) LTD.

    PONTIFAX (CHINA) IV L.P.

    PONTIFAX (CAYMAN) IV L.P.

    PONTIFAX (ISRAEL) IV, L.P.

    PONTIFAX IV GP L.P.

    • 10% Owner
    8,077,410 2021-05-13 0

    RAKERS GARY D. CONTROLLER, PFO/PAO, TREASURER

    0 2021-03-24 0

    WILLIAMS GREGORY C. CHIEF EXECUTIVE OFFICER

    194,629 2021-02-25 0

    MACDONALD STEPHEN G. VP FINANCE & ACCTG, TREASURER

    0 2021-02-12 0

    NOIMAN SILVIA

    0 2020-05-20 0

    KLEIJWEGT MARTIJN

    0 2020-05-20 0

    PONTIFAX MANAGEMENT 4 G.P. (2015) LTD.

    PONTIFAX IV GP L.P.

    PONTIFAX (CAYMAN) IV L.P.

    PONTIFAX (CHINA) IV L.P.

    PONTIFAX (ISRAEL) IV, L.P.

    PONTIFAX MANAGEMENT III G.P. (2011) LTD.

    PONTIFAX MANAGEMENT FUND III L.P.

    PONTIFAX (CAYMAN) III, L.P.

    PONTIFAX (ISRAEL) III, L.P.

    • 10% Owner
    0 2020-05-20 0

    WEAVER GREGORY L

    • FORMER CHIEF FINANCIAL OFFICER
    No longer subject to file 2020-03-15 0

    WARD ROBERT

    • FORMER CHAIRMAN AND CEO
    No longer subject to file 2020-02-29 0

    SNOW DAVID P.

    • FORMER CHIEF BUSINESS OFFICER
    No longer subject to file 2020-02-29 0

    PONTIFAX MANAGEMENT III G.P. (2011) LTD.

    PONTIFAX MANAGEMENT FUND III L.P.

    PONTIFAX (CAYMAN) III, L.P.

    PONTIFAX (ISRAEL) III, L.P.

    • 10% Owner
    0 2018-06-15 0

    HUERTAS PEDRO CHIEF MEDICAL OFFICER

    • Officer
    137,725 2018-05-16 0

    SHABTAI GILAD

    • 10% Owner
    3,351,770 2018-04-30 0

    FROST PHILLIP MD ET AL

    • SEE REMARKS
    No longer subject to file 2017-12-19 0

    OPKO HEALTH, INC.

    • 10% Owner
    No longer subject to file 2017-12-19 0

    RECTOR DAVID

    • SEE REMARKS
    No longer subject to file 2017-12-19 0

    BRACA JOHN N

    • SEE REMARKS
    No longer subject to file 2017-12-19 0

    HEFT ROBERT

    • Director
    0 2017-12-19 0

    WAKSAL HARLAN

    • Director
    0 2015-11-19 0

    FROST PHILLIP MD ET AL

    FROST GAMMA INVESTMENTS TRUST

    • Director
    • 10% Owner
    1,598,170 2015-09-29 0

    FORBES CHRISTOPHER

    • Director
    0 2014-11-18 0

    MARTELL RON CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    0 2014-11-18 0

    BROOKS JOEL CHIEF FINANCIAL OFFICER

    • Officer
    0 2014-11-18 0

    THOMPSON JOHN PHD SCIENTIFIC FOUNDER

    • Officer
    0 2014-11-18 0

    DONDERO RICHARD S VP - PRECLINICAL RESEARCH

    • Officer
    0 2014-11-18 0

    BROWNE LESLIE J PRESIDENT

    • Officer
    0 2014-11-18 0

    SMIDER VAUGHN CHIEF SCIENTIFIC OFFICER

    • Officer
    • Director
    • 10% Owner
    0 2014-11-18 0

    GRAZIANO JAMES JOSEPH CHIEF TECHNOLOGY OFFICER

    • Officer
    0 2014-11-18 0

    RIOS MIGUEL DE LOS VP - RESEARCH

    • Officer
    0 2014-11-18 0

    STALDER RUEDI

    • Director
    No longer subject to file 2014-05-16 0

    QUICK THOMAS C

    • Director
    No longer subject to file 2014-05-16 0

    VAN HULST JACK

    • Director
    No longer subject to file 2014-05-16 0

    ISABELLE WARREN JOHN

    • Director
    No longer subject to file 2014-05-16 0

    KLAVER PAUL EDWARD

    • 10% Owner
    17,293,054 2012-03-15 0

    GALTON BRUCE C

    • FORMER PRESIDENT & CEO
    98,450 2009-11-30 0

    FEDYSZYN SASCHA P VP - CORPORATE DEV.

    • Officer
    153,460 2009-11-19 0

    PARTLET HOLDINGS LTD

    • 10% Owner
    2,111,111 2009-11-11 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    AVNUR ZAFRIRA - Director

    2022-06-17 08:23:51 -0400 2022-06-15 A 20,000 a 20,000 direct

    KARIV TOMER - Director

    2022-06-17 08:24:38 -0400 2022-06-15 A 20,000 a 20,000 direct

    RUBIN STEVEN D - Director

    2022-06-17 08:27:49 -0400 2022-06-15 A 20,000 a 20,000 direct

    PAREKH RAJESH B - Director

    2022-06-17 08:27:06 -0400 2022-06-15 A 20,000 a 20,000 direct

    NUSSBAUM RAN - Director

    2022-06-17 08:26:16 -0400 2022-06-15 A 20,000 a 20,000 direct

    VEINRIB GADI - Director

    2022-06-17 08:28:59 -0400 2022-06-15 A 20,000 a 20,000 direct

    SEEHRA JASBIR - Director

    2022-06-17 08:28:16 -0400 2022-06-15 A 20,000 a 20,000 direct

    WALTS ALAN EDMUND - Director

    2022-06-17 08:29:27 -0400 2022-06-15 A 20,000 a 20,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 22:15:03 UTC -1.5496 3.1196 100000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 21:45:03 UTC -1.5496 3.1196 100000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 21:15:04 UTC -1.5496 3.1196 100000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 20:45:03 UTC -1.5496 3.1196 100000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 20:15:03 UTC -1.5496 3.1196 100000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 19:45:03 UTC -1.5496 3.1196 100000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 19:15:03 UTC -1.5496 3.1196 100000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 18:45:03 UTC -1.4668 3.0368 100000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 18:15:04 UTC -1.4668 3.0368 100000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 17:45:03 UTC -1.4668 3.0368 150000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 17:15:03 UTC -1.4668 3.0368 150000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 16:45:03 UTC -1.4668 3.0368 150000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 16:15:03 UTC -1.4668 3.0368 150000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 15:45:03 UTC -1.4668 3.0368 100000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 15:15:03 UTC -1.4668 3.0368 35000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 14:45:03 UTC -1.4325 3.0025 35000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 14:15:03 UTC -1.4325 3.0025 45000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 13:45:03 UTC -1.4325 3.0025 45000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 13:15:03 UTC -1.4325 3.0025 45000
    ELOXX PHARMACEUTICALS INC ELOX 2022-06-24 12:45:03 UTC -1.4325 3.0025 45000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments